Merck Global Health Innovation Fund and existing investor Cedars-Sinai took part in a $17m round for the blood collection technology provider.
Tasso, the US-based creator of a home blood-sampling kit, closed a $17m series A round on Wednesday featuring healthcare provider Cedars-Sinai as well as pharmaceutical firm Merck & Co.
Venture capital firm Hambrecht Ducera Growth Ventures led the round, which was also backed by Foresite Capital, Vertical Venture Partners and Techstars, while Merck participated through its Global Health Innovation Fund.
Founded in 2011, Tasso has developed a system called OnDemand which allows users to collect blood samples at home through…
